Eikon Therapeutics at Cantor conference: selective cancer drugs advance

Eikon Therapeutics (NASDAQ:EIKN) is developing PARP1 inhibitors EIK1003 and EIK1004, targeting cancer treatments. EIK1003 is being tested in combinations with paclitaxel, carboplatin, and abiraterone. EIK1004 is designed for brain penetration. The company also has EIK1005, a Werner helicase inhibitor, in early studies. Eikon aims to address unmet medical needs in oncology.

Eikon Therapeutics filed an 8-K to provide an updated corporate presentation and clinical updates. For EIK1001 (TLR7/8) TeLuRide-005, fully enrolled, NSCLC ORR was 63.1% with median DOR over 11 months as of May 4, 2026, and Grade ≥3 drug-related TRAEs were 48.6%. EIK1003 showed ORR 14.3% (monotherapy) and 24.5% (combo).

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates • Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology

Baker Hughes reported Q2 earnings of 64 cents per share, which it said beat analyst consensus of 50 cents, and quarterly sales of $6.742 billion versus $6.523 billion expected. The stock rose 8.2% to $61.97 on Monday. The article also notes broad gains in U.S. equities.

Ionis Pharmaceuticals (IONS) shares have fallen over 40% this year, despite analysts maintaining an average price target of $83.82. The company has six approved therapies, primarily for rare diseases, and is developing eight more in late-stage trials. Ionis reported a 40.7% revenue decline and a net loss in Q2, but analysts highlight its antisense oligonucleotide technology and potential for future growth.

GLOBALFOUNDRIES (GFS) secured $375M in CHIPS R&D funding and $300M for silicon photonics. Its stock rose 4.32% recently, but is down 46.67% over 90 days. Analysts value it at $76, 37% above its last close of $47.82, citing its global manufacturing and government incentives. However, risks include weak smartphone demand and high capital spending.